Comparative Pharmacology
Head-to-head clinical analysis: INDOCIN versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDOCIN versus TOLECTIN DS.
INDOCIN vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. It also decreases renal blood flow and may cause ductus arteriosus closure.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
25 mg orally 2-3 times daily; maximum 200 mg/day. Intravenous: 0.5-1 mg/kg as single dose for ductus arteriosus closure.
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 4.5 hours (range 2.6–11.2 hours); prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Renal (60% as unchanged drug and glucuronide conjugates), biliary/fecal (33% via enterohepatic circulation).
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category C
Category C
NSAID
NSAID